Baillie Gifford & Co
NVAX icon

Baillie Gifford & Co’s Novavax NVAX Stock Holding History

Baillie Gifford & Co’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-130
Closed -$901 – 394
2023
Q1 		$901 Hold
130
– – ﹤0.01% 445
2022
Q4 		$1.34K Hold
130
– – ﹤0.01% 474
2022
Q3 		$2K Hold
130
– – ﹤0.01% 471
2022
Q2 		$7K Hold
130
– – ﹤0.01% 440
2022
Q1 		$10K Hold
130
– – ﹤0.01% 434
2021
Q4 		$19K Buy
+130
New +$22.3K ﹤0.01% 386

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baillie Gifford & Co's NVAX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Novavax (NVAX) in Q2 2023, closing a stake of 130 shares — an estimated $901 sold.

Baillie Gifford & Co first reported a position in NVAX in Q4 2021 and held it in 6 quarters. The position peaked at $19K in Q4 2021. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 130 Novavax shares in Q2 2023, an estimated $901.
  • Baillie Gifford & Co first reported a position in Novavax in Q4 2021 and held it in 6 quarters.
  • Baillie Gifford & Co's Novavax position peaked at $19K in Q4 2021.
  • 215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.